Cerebral collateral circulation provides alternative vascular routes for blood to reach ischemic tissues during stroke. Collateral therapeutics attempt to augment flow through these collateral channels to reduce ischemia and brain damage during acute ischemic stroke. Transient aortic occlusion (TAO) has pre-clinical data suggesting that it can augment collateral blood flow and clinical data suggesting a benefit for patients with moderate cortical strokes. By diverting blood from the periphery towards the cerebral circulation, TAO has the potential to augment primary collateral flow at the circle of Willis and thereby improve outcome even during large, hemispheric strokes. Using proximal middle and anterior cerebral artery occlusion in rats, we demonstrate that TAO reduces mortality and improves collateral blood flow in severely ischemic animals. As such, TAO may be an effective therapy to reduce early mortality during severe ischemia associated with proximal occlusions.

Keywords Stroke · Collateral blood flow · Ischemia · Neuroprotection · Collateral therapeutics · Cerebral blood flow

Collateral circulation refers to pre-existing vascular redundancies that provide a route for blood to reach a target tissue when a primary channel is blocked [1–5]. Primary cerebral arterial collaterals refer to short arterial segments in the circle of Willis that allow blood flow between the territories of the internal carotid arteries and the vertebrobasilar system or between cerebral hemispheres in the event of proximal occlusion. The secondary cerebral collaterals include the pial (or leptomeningeal) collaterals, which are anastomotic connections located on the surface of the cortex that connect distal branches of the anterior, middle, and posterior cerebral arteries (ACA, MCA, PCA). These collateral channels permit blood flow from the territory of an unobstructed artery into the territory of an occluded artery (e.g., retrograde filling of the MCA territory via anastomoses with the ACA after middle cerebral artery occlusion (MCAo)) [2–4, 6]. Collateral extent is crucial, as in both animal models and human stroke patients the degree of collateral perfusion during cerebral ischemia is a predictor of stroke severity, prognosis, and response to reperfusion therapy [7–15].

“Collateral therapeutics” augment blood flow through collaterals to improve perfusion of penumbral tissue during acute ischemic stroke. Recently, promising pre-clinical and clinical data support the use of transient aortic occlusion (TAO) to increase global cerebral perfusion and reduce damage due to stroke. Pre-clinical work in TAO-treated rats has demonstrated reduced infarct size [16] and augmentation of flow through pial collaterals due to TAO after thromboembolic MCAo [17]. Data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial suggests that TAO is safe and improves stroke outcome in subsets of stroke patients [4, 16, 18–21]. Patients with cortical ischemic stroke presenting within 5 h of onset, with National Institutes of Health Stroke Scale (NIHSS) between 8 and 14 (moderate severity), and patients older than 70 years of age showed the greatest benefit from TAO [19]. Additional analysis of the SENTIS trial reports a
significant reduction in stroke-related mortality and severe disabil-
ity with TAO [22]. Notably, the mortality difference was con-
centrated in the patients at highest risk (NIHSS scores >14 and those older than age 70) [19, 20]. This reduction in stroke-
related mortality in patients with severe stroke suggests that
TAO may be beneficial for patients with proximal occlusions
resistant to intravenous thrombolysis, such as internal carotid
occlusions or proximal occlusion of the MCA [23, 24]. Here,
we evaluated the efficacy of TAO to improve collateral blood
flow and reduce mortality in a model of proximal MCA/ACA
occlusion.

Methods

Experimental protocols conform to the guidelines established
by the Canadian Council on Animal Care and were approved
by the Health Sciences Animal Care and Use Committee at
University of Alberta. Urethane-anaesthetized (i.p., 1.5 g/kg
in sterile saline) male Sprague Dawley rats (400–450 g, 3–
4 months of age) divided into two treatment groups (MCAo +
TAO, n = 10; MCAo + Sham TAO, n = 11) underwent laser
speckle contrast imaging (LSCI) through a thinned-skull im-
aging window. LSCI maps of blood flow were acquired at
baseline, post-MCAo, 15 min after cessation of TAO (or
sham, 2 h post-MCAo), and 75 min after TAO (or sham, 3 h
post-MCAo). Immediately after the final imaging session, an-
imals were euthanized and their brains were removed. Early
indices of infarct size and location were assessed on cryostat-
sectioned 20-μm coronal brain sections stained with hematoxy-
lin and eosin (H&E). Animals that did not survive through all
imaging sessions (4, all from the sham-TAO group) or with
poor image quality (1, due to degradation of the optical win-
dow) were excluded from LSCI analyses.

LSCI

LSCI was performed via a ~5 × 5-mm thin skull cranial window
over the distal regions of the MCA territory [6, 17, 25]. Back-
scattered light was collected by a Dalsa 1M60 Pantera CCD
camera (5 ms exposure time) during illumination with a 784-
nm (32 mW) laser (StockerYale, Inc.). Speckle contrast (K = σ/%
I) was determined using ImageJ software (NIH) [6, 26]. Maps of
K show the pattern of blood flow on the cortical surface during
imaging, with darker vessels demonstrating relatively faster
flow than lighter vessels. K values were converted to cor-
relation times (τc) that are approximately inversely proportional
to blood flow velocity [17, 26, 27]. Data are expressed as
τBaseline/τc or τMCAo/τc, values that illustrate changes in blood flow
from baseline or post-MCAo values, respectively. Vessel diam-
eters were determined using an ImageJ plug-in that uses a full
width at half-maximum algorithm [17, 28].

Filament Occlusion

To induce proximal occlusions of the MCA and ACA, the
right common, internal, and external carotid arteries (CCA,
ICA, ECA) were exposed. A silicon rubber-coated monofil-
ament (Doccol Corporation, filament size 3-0, diameter
0.20 mm, length 30 mm; diameter with coating 0.54+/-
0.02 mm; coating length 5–6 mm) was advanced through
the ECA into the ICA until lodging proximal to the origin of
MCA and ACA and then sutured in place.

Transient Aortic Occlusion

To transiently occlude the descending aorta [16, 17], a dilation
catheter (2.0 mm diameter, Cordis Fire Star RX PTCA) was
advanced past the origin of the renal artery from the femoral
artery. Aortic flow diversion was initiated 60 min after ische-
mic onset and maintained for 45 min.

Results

LSCI was performed to monitor the blood flow in cortical
surface vessels during proximal MCA and ACA occlusion
followed by TAO (n = 10) or Sham-TAO (n = 11). Consistent
with previous studies, anastomoses between distal ACA and
MCA segments were apparent after MCAo but not during
delayed imaging (Fig. 1a, b, white arrows). Qualitative anal-
ysis of LSCI data showed clear decreases in blood flow by
MCAo and increased flow that persists after TAO in some but
not all TAO-treated rats (Fig. 1d, note an increase in speckle
contrast after MCAo that reflects a reduction in flow and a
darkening of the image as blood flow increases due to TAO).
Arrows in Fig. 1c show regions of drastic increases in flow in
MCA segments downstream of ACA-MCA anastomoses in a
TAO-treated animal. In other animals (from both treatment
groups), reductions in flow after MCAo were less drastic
and distinct changes due to TAO or sham were not apparent
(Fig. 1b). Notably, early mortality (between 1 and 3 h after
ischemic onset, prior to completion of the final imaging ses-
son 3 h after ischemic onset) was significantly reduced in
TAO-treated rats relative to Sham-TAO (Fig. 1d, P = 0.034). Analysis of blood flow (τBaseline/τc)
in distal MCA segments downstream of ACA anastomoses after
MCAo but prior to treatment (or sham) suggests that
early mortality occurred in Sham-TAO rats with severe ische-
emia (Fig. 1e). Multivariate analyses of physiological param-
eters monitored via pulse oximetry (Table 1) did not reveal any
differences in oxygen saturation, heart rate, or breath rate that
could account for differences in early mortality.

Because early mortality resulted in group differences in
post-MCAo blood flow, τc were normalized to post-MCAo
values within each animal to examine treatment-induced
changes in blood flow in distal MCA segments and in surface veins draining the ischemic territories (Fig. 2a, b). Multivariate ANOVA did not reveal a significant main effect of treatment on $\tau_{MCAo}/\tau_c$ (MCA segments, $F_{(1, 14)} = 3.020$, $P = 0.1042$; veins, $F_{(1, 14)} = 2.306$, $P = 0.1511$). However, a clear trend towards augmented collateral flow in MCA segments was apparent in a subset of TAO-treated rats. Notably, drastic increases in flow after TAO did not occur in any Sham-TAO animals. TAO Responders were therefore defined as animals in which $\tau_{MCAo}/\tau_c$ was greater than the mean $\tau_{MCAo}/\tau_c$ from sham animals plus two standard deviations [5/9 (56 %) of rats in the TAO group met this criteria; see Fig. 1c for representative speckle contrast images showing increased flow]. Vessel diameter (normalized to baseline diameter, measured 75 min after cessation of TAO or Sham-TAO) was not significantly different between treatment groups in MCA segments or surface veins (Fig. 2c, d) (unpaired $t$ test, $P > .05$). However, single sample $t$ tests (hypothetical baseline of 1.0) suggest that MCA segments were significantly dilated relative to baseline only in the TAO group ($P = .032$).

**TAO Responders Versus Non-responders**

A variance-stabilizing log transformation of MCA flow ([log($\tau_{MCAo}/\tau_c$)], Fig. 2a) was performed to better visualize response patterns. Figure 2e shows log($\tau_{MCAo}/\tau_c$) data from
Infarct volume was 93.84 ± 21.92 mm$^3$ in TAO-treated rats. Sures tests on MCAo / greater increases in log($\tau$ & sons demonstrating that TAO responders had significantly increases in blood flow after MCAo / responders or sham animals (\. While multivariate ANOVA did not identify a significant main effect, significant increases in blood flow from post-MCAo values were observed in some (5/9) TAO-treated rats. No comparable changes in flow were observed in sham-TAO rats. Δ Diameter of distal MCA segments and surface veins, respectively, measured 75 min after cessation of TAO or Sham-TAO. # denotes a significant difference from a hypothetical (normalized) baseline value of 1.0 on a single sample t test. Δ A variance-stabilizing transformation was achieved by performing a log transform of $\tau_{MCAo}/\tau_c$ values. e, f Multivariate ANOVA detected a significant effect of group on log($\tau_{MCAo}/\tau_c$) when rats were categorized as TAO “responding” or “non-responding” (i.e., rats that exhibited a clear increase in MCA flow after TAO vs. rats with no significant change in MCA flow) or sham-TAO. **** denotes significant (P < .0001) Holm-Sidak post hoc comparisons. g, b $\tau_{Baseline}/\tau_c$ values from TAO responders and non-responders, respectively, showing that TAO responders had severe ischemia prior to treatment that was normalized near baseline values by TAO (whereas TAO non-responders had less severe ischemia and no change due to treatment). i Representative H&E-stained tissue sections showing demarcation of early infarct from healthy tissue (black arrows, distances from Bregma shown below images). j Pooling $\tau_{Baseline}/\tau_c$ values across treatment groups, a clear inverse relationship between amount of blood flow (relative to baseline) in distal MCA segments (measured 75 min after TAO or sham-TAO, 2 h after MCAo onset) and the volume of early infarct detected 3 h after MCAo onset.

MCA segments in TAO-treated rats, indicating a clear separation of rats who responded to TAO with an increase in collateral flow ($\tau$, denoted by dashed line) or did not respond to treatment (\. Multivariate ANOVA of log($\tau_{MCAo}/\tau_c$) for TAO “responders,” TAO “non-responders,” and Sham-TAO rats (Fig. 2f) revealed a significant main effect of group ($F(2, 13) = 26.59$, $P < 0.0001$), with Holm-Sidak post hoc comparisons demonstrating that TAO responders had significantly greater increases in log($\tau_{MCAo}/\tau_c$) relative to TAO non-responders or sham animals ($P < .0001$). Notably, TAO responders had very low blood flow after MCAo ($\tau_{Baseline}/\tau_c = 0.06 ± 0.016$ or ~6% of baseline) and showed a drastic increase after TAO (Fig. 2g). Non-responders had more moderate ischemia ($\tau_{Baseline}/\tau_c = 0.38 ± 0.14$ or ~38% of baseline) and no change after TAO (Fig. 2h). Friedman’s repeated measures tests on $\tau_{Baseline}/\tau_c$ in responders and non-responding animals confirmed a statistically significant relationship between TAO and blood flow in TAO responders ($\chi^2(3) = 7.60$, $P = .0239$) but not non-responders ($P > .05$).

Discussion

In the SENTIS trial, 515 patients with cortical ischemic stroke received 45 min of TAO or standard stroke treatment. SENTIS data suggest that TAO is safe and may be an effective therapy for subsets of stroke patients [18–20, 22, 29]. These trials in cortical stroke patients suggested maximal treatment efficacy for those with moderate stroke severity [19]. By redistributing blood towards the head from the peripheral circulation, TAO has the potential to augment both primary (circle of Willis) and secondary (pial) collateral flows [1, 2]. Here, using a large filament-based occlusion to block the origins of the MCA and ACA, we evaluated whether TAO could improve collateral blood flow and reduce mortality during severe stroke. Because this model would occlude the origins of the ACA and MCA, enhanced collateral flow through the circle of Willis (i.e., through the anterior and/or posterior communicating arteries) would be required to reduce ischemia and

**Table 1** Physiological parameters

| Time         | Oxygen saturation | Heart rate | Breath rate |
|--------------|-------------------|------------|-------------|
| Pre-MCAo     |                   |            |             |
| TAO          | Mean 98.83        | 366.75     | 100.43      |
| S.E.M 0.38   | 10.69             | 5.92       |             |
| Sham—survived| Mean 99.09        | 386.76     | 97.55       |
| S.E.M 0.34   | 20.66             | 6.80       |             |
| Sham—died    | Mean 99.45        | 365.26     | 85.22       |
| S.E.M 0.05   | 22.84             | 7.61       |             |
| Post-MCAo    |                   |            |             |
| TAO          | Mean 98.84        | 389.54     | 96.53       |
| S.E.M 0.14   | 11.91             | 6.56       |             |
| Sham—survived| Mean 99.18        | 414.15     | 89.58       |
| S.E.M 0.22   | 20.28             | 3.22       |             |
| Sham—died    | Mean 99.56        | 394.81     | 86.03       |
| S.E.M 0.05   | 22.84             | 7.61       |             |
| Post-TAO or sham |         |            |             |
| TAO          | Mean 95.98        | 404.40     | 96.99       |
| S.E.M 0.93   | 13.15             | 5.68       |             |
| Sham—survived| Mean 98.20        | 381.01     | 94.99       |
| S.E.M 1.08   | 31.18             | 8.85       |             |

Multivariate analyses of physiological parameters monitored via pulse oximetry did not reveal any differences in oxygen saturation, heart rate, or breath rate that could account for differences in early mortality.

Histology

Early infarct was visualized using H&E staining (Fig. 2i). Infarct volume was 93.84 ± 21.92 mm$^3$ in TAO-treated rats and 107.1 ± 36.89 mm$^3$ in Sham-TAO rats (unpaired t test, $P > .05$). While difference in pre-treatment but post-MCAo flow in animals that survived to 3-h post-MCAo makes comparisons between treatment groups difficult, plotting infarct volume as a function of blood flow ($\tau_{Baseline}/\tau_c$) in MCA segments 75 min after TAO or Sham-TAO illustrates a clear inverse relationship between collateral flow and early infarct volume (Fig. 2j).
mortality. Our data show a significant reduction in early mortality with TAO. Moreover, LSCI data suggest that in animals with severe ischemia, TAO can improve flow in MCA segments downstream of ACA anastomoses and reduce ischemia. In animals with more moderate ischemia, TAO did not induce significant increases in blood flow. This may suggest that in animals or patients with effective primary collaterals, TAO does not further enhance flow. However, in severe ischemia associated with poor primary collateral flow and high mortality [30], TAO may be an effective acute therapy to maintain blood flow to ischemic regions at a level sufficient to prevent early mortality.

While promising, it is important to note that our measure of early mortality may not reflect total mortality outside the acute period. Previous reports suggest that mortality after permanent MCAo in Sprague Dawley rats results in the days following...
ischemic onset rather than the first few hours [31]. As such, our early mortality was surprising. However, our occlusion model used a large calibre (~0.54 mm including coating) filament to block carotid flow to the ACA and MCA, and this severe ischemia may account for the early mortality. Consistent with this interpretation, mortality of 13 % in the first 24 h has been reported after MCAo with 0.193-mm diameter filaments, whereas smaller filaments (0.180 mm) produced smaller infarcts and did not result in mortality in this period [32]. We observed increased TAO efficacy (greater increase in flow relative to post-stroke levels) in rats with severe ischemia prior to treatment, and early mortality may result from this severe ischemia in untreated rats. However, while we postulate a mechanism involving augmentation of primary collateral flow (via the circle of Willis), this was not verified by our imaging (which measured flow in surface arteries downstream of any increases in primary collateral flow). Nonetheless, the current data suggests that TAO warrants further investigation as a stand-alone neuroprotective strategy to reduce acute mortality after severe stroke and as an adjunct therapy to maintain tissue viability during treatment of severe ischemic stroke.

Compliance with Ethical Standards

Funding This work was supported by the Canadian Institutes of Health Research (IRW, 110967) and Alberta Innovates Health Solutions (Scholarship Award, IRW, 200900509).

Conflict of Interest The authors have no conflicts of interest.

Ethical Approval All applicable international, national, and institutional guidelines for the care and use of animals were followed.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Liebeskind. Collateral circulation. Stroke. 2003;34:2279–84.
2. Liebeskind. Neuroprotection from the collateral perspective. iDRugs. 2005;8:222–8.
3. Ramakrishnan G, Armitage GA, Winship IR. Acute Ischemic Stroke. In: Julio César García Rodríguez, Ed. (InTech Open Access Publisher, ed. doi:10.5772/1438.
4. Shuaib A, Butcher K, Mohammad AA, Saqur M, Liebeskind DS. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol. 2011;10:909–21.
5. Winship. Cerebral collaterals and collateral therapeutics for acute ischemic stroke. Microcirculation. 2015;22:228–36.
6. Armitage, Todd KG, Shuaib A, Winship IR. Laser speckle contrast imaging of collateral blood flow during acute ischemic stroke. J Cereb Blood Flow Metab. 2010;30:1432–6.
7. Zhang P, Prabhakar R, Sealock, Faber JE. Wide genetic variation in the native pial collateral circulation is a major determinant of variation in severity of stroke. J Cereb Blood Flow Metab. 2010;30:923–34.
8. Bang JL, Saver BH, Buck JR, Alger S, Starkman B, Ovbiagele D, et al. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2008;79:625–9.
9. Bang JL, Saver SJ, Kim GM, Kim CS, Chung B, Ovbiagele KH, et al. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke. 2011;42:2235–9.
10. Menon B, O’Brien A, Bivard NJ, Spratt AM, Demchuk F, Miteff X, et al. Assessment of leptomeningeal collaterals using dynamic CT angiography in patients with acute ischemic stroke. J Cereb Blood Flow Metab. 2013;33:365–71.
11. Menon EE, Smith SB, Couts DG, Welsh JE, Faber M, Goyal MD, et al. Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol. 2013;74:241–8.
12. Lima KL, Furie GS, Silva MH, Lev EC, Camargo AB, Singhal GJ, et al. The pattern of leptomeningeal collaterals on CT angiography is a strong predictor of long-term functional outcome in stroke patients with large vessel intracranial occlusion. Stroke. 2010;41:2316–22.
13. Liebeskind. Of mice and men: essential considerations in the translation of collateral therapeutics. Stroke. 2008;39:e187–8. Author reply e189.
14. Bang JL, Saver SJ, Kim GM, Kim CS, Chung B, Ovbiagele KH, et al. Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke. 2011;42:693–9.
15. Christoforidis, Karakasis C, Mohammad Y, Caragine LP, Yang M, Slivka AP. Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: the role of pial collateral formation. AJNR Am J Neuroradiol. 2009;30:165–70.
16. Noor, Wang CX, Todd K, Elliott C, Wahr J, Shuaib A. Partial intra-aortic occlusion improves perfusion deficits and infarct size following focal cerebral ischemia. J Neuroimaging. 2010;20:272–6.
17. Winship, Armitage GA, Ramakrishnan G, Dong B, Todd KG, Shuaib A. Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion. J Cereb Blood Flow Metab. 2014;34:61–71.
18. Shuaib A, Schwab S, Rutledge JN, Starkman S, Liebeskind DS, Bernardini GL, Boulos A, Abou-Chebl A, Huang DY, Vanhooren G, Cruz-Flores S, Klucznik RP, Saver JL, SENTIS trial investigators. Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial. J Neurointerv Surg 2013. doi:10.1136/neurintsurg-2012-010562.
19. Shuaib A, Bornstein NM, Diener HC, Dillon W, Fisher M, Hammer MD, et al. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke Trial. Stroke. 2011;42:1680–90.
20. Leker, Molina C, Cockcroft K, Liebeskind DS, Concha M, Shuaib A, et al. Effects of age on outcome in the SENTIS trial: better outcomes in elderly patients. Cerebrovasc Dis. 2012;34:263–71.
21. Emery, Schellinger PD, Selchen D, Douen AG, Chan R, Shuaib A, et al. Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke. 2011;42:1135–7.

 Springer
22. Schellinger, Shuaib A, Kohrmann M, Liebeskind DS, Jovin T, Hammer MD, et al. Reduced mortality and severe disability rates in the SENTIS trial. AJNR Am J Neuroradiol. 2013;34:2312–6.

23. Lee, Han SW, Kim SH, Nam HS, Ahn SW, Kim DJ, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke. 2007;38:192–3.

24. Wolpert, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3–13.

25. Winship. Laser speckle contrast imaging to measure changes in cerebral blood flow. Methods Mol Biol. 2014;1135:223–35.

26. Dunn. Laser speckle contrast imaging of cerebral blood flow. Ann Biomed Eng. 2012;40:367–77.

27. Boas, Dunn AK. Laser speckle contrast imaging in biomedical optics. J Biomed Opt. 2010;15:011109.

28. Fischer, Uchida S, Messlinger K. Measurement of meningeal blood vessel diameter in vivo with a plug-in for ImageJ. Microvasc Res. 2010;80:258–66.

29. Bernardini, Schellinger PD, Abou-Chebl A, Cockroft K, Shuaib A, Sheorajpanday R, et al. Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014;23:1457–61.

30. Steiner, Ringleb P, Hacke W. Treatment options for large hemispheric stroke. Neurology. 2001;57:S61–8.

31. Carmichael. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx. 2005;2:396–409.

32. Kuge Y, Minematsu K, Yamaguchi T, Miyake Y. Nylon monofilament for intraluminal middle cerebral artery occlusion in rats. Stroke. 1995;26:1655–7. discussion 1658.